Retina

SemaThera Inc. has announced a research collaboration and licensing agreement with Roche to develop a new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

Investigators observe dramatic decrease in treatment burden seen in OPTIC study.

Protocol V delves into observation of disease.

Investigators set out to determine if treatment crosses blood-retina barrier.

Technology helps physicians understand normal and abnormal macular anatomy.

Graybug Vision, Inc. has reported preliminary topline data from a 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

Transient sensory-motor abnormalities are often common.

Treatment may facilitate sight in end-stage retinitis pigmentosa.

Baseline diabetic retinopathy severity is an important predictor of its progression in patients.

Women 34% less likely to receive retinal detachment repair.

Tool can help physicians detect, monitor ophthalmic disease in their patients.

Visits, elective procedures decreased as physicians responded to COVID-19 guidelines.

Treatment of patients with COVID-19 should include ophthalmic considerations.

Studies look at absorption of drugs resulting in systemic complications.

Key is to recognize usual patterns for systemic and topical medications.

Precision injection device can improve patient and physician experiences.

Analysis finds drug is broadly effective for reducing diabetic retinopathy severity.

Investigators find no clinically relevant differences in safety profiles.

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

An ophthalmologist’s thoughts while folding clothes.

Study examining the role of IL-17A in patients with diabetes.

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

Investigators focus on biophysical method to study protein-protein interactions .

While current treatments are good, the best is yet to come.

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.